Defined GalNAc architecture • P(III) integrity • Solid-phase compatibility
BOC Sciences supports custom GalNAc phosphoramidite synthesis for incorporation into research oligonucleotides by solid-phase chemistry. Projects define the GalNAc ligand, linker, phosphoramidite attachment site, and protection pattern, with material characterization and optional coupling evaluation scoped for the intended synthesis cycle.
Conceptual example of a multivalent GalNAc reagent workflow. Ligand valency, incorporation position, and synthesis-cycle compatibility are defined separately.Project specification
Custom synthesis scope
GalNAc phosphoramidite is a family description, not a unique molecular structure. Monovalent building blocks, preassembled ligand clusters, and different linkers can have different coupling and deprotection requirements. The target drawing specifies every component, including whether an additional protected hydroxyl is available for continued chain extension.
Prepare a specified single-GalNAc building block carrying the requested linker and phosphoramidite functionality. The ligand stereochemistry, branch-point identity, and any hydroxyl protecting group are defined explicitly. Multiple incorporations may build a ligand arrangement, but the number and spacing of residues depend on the oligonucleotide design and supported coupling sequence.
Discuss a preassembled GalNAc cluster with defined valency, branching scaffold, linker length, and phosphoramidite attachment site. A triantennary ligand is one specified architecture, not an interchangeable description for every three-GalNAc construct. Steric size, solubility, and reagent purity are considered in relation to the intended coupling.
Assess a requested spacer, branch point, or protection change against the oligonucleotide cycle. A building block intended for internal incorporation needs a compatible continuation site and removal sequence. A reagent without that functionality may be suitable only for a terminal addition. Compatibility is defined for the exact structure rather than inferred from the GalNAc name.
Add an agreed evaluation using a specified oligonucleotide, support, activator, and cycle. The test can examine conversion, conjugate identity, and relevant side products after cleavage and deprotection. A model result is reported within its tested conditions and does not establish universal instrument, sequence, or backbone compatibility.

Target-specific route assessment
The ligand precursor and P(III) reagent require different handling considerations. Route planning connects selective phosphitylation with the purity, packaging, and solution behavior needed for the intended solid-phase operation.
Unintended exposed hydroxyls can generate differently phosphitylated or multifunctional species. The precursor protection pattern and target attachment site are reviewed before the final step. The GalNAc ligand remains structurally defined rather than being represented only by a phosphorus-containing mass.
Phosphoramidites are susceptible to hydrolysis and oxidation. Dry handling and protection from incompatible exposure are therefore planned for the material and its solution preparation. Water content and phosphorus-species analysis answer different questions; neither should be substituted for the other.
Coupling, capping, oxidation or sulfurization, acid treatment, cleavage, and deprotection can each affect the reagent or final ligand. The applicable sequence depends on whether the GalNAc unit is terminal or internal. Solubility at the intended concentration is considered alongside chemical stability.
Material and project decisions
Acceptance criteria should connect a measurement to the decision it supports. No single assay establishes ligand identity, P(III) integrity, dryness, and functional performance at the same time.
| Acceptance question | Measurement or test | What it establishes | Boundary |
|---|---|---|---|
| Is the intended ligand present? | Appropriate 1H/13C NMR and mass analysis | Consistency with GalNAc, linker, and protected derivative identity | Does not alone establish coupling efficiency |
| What phosphorus species are detected? | 31P NMR under recorded conditions | Phosphorus environments and detectable related P-containing species | Peak count or area alone is not universal chemical purity |
| Is water content suitable for use? | A justified water-content method, such as an appropriate Karl Fischer method | Water result for the tested sample and method | Requires method suitability for the sensitive matrix |
| Is chemical purity acceptable? | A compatible chromatographic method and defined reporting basis | Detectable precursor and related chemical species | UV area may not represent all nonchromophoric impurities equally |
| Will the reagent work in the intended cycle? | A defined coupling, cleavage, and deprotection test | Performance for the tested construct and conditions | Does not prove compatibility with all sequences or supports |
Our Glycoconjugate Synthesis Service provides broader conjugation context. Reagent synthesis, complete oligonucleotide manufacture, and biological evaluation are separate project scopes.
Structure-to-data consistency
The analytical package addresses both the carbohydrate ligand and the reactive phosphorus functionality. Proposed specifications are set for the actual molecular structure, without assuming a universal phosphorus shift, purity threshold, or coupling yield.
Phosphorus
Record solvent, reference, acquisition conditions, and the relevant phosphorus signals. A phosphoramidite with a stereogenic phosphorus center can display diastereomeric signals in a chiral molecule; those signals do not automatically indicate an impurity. Hydrolysis or oxidation assignments need suitable supporting evidence.
Ligand identity
Suitable NMR and mass data support the GalNAc configuration, linker, protection pattern, and intended derivative. The analytical approach accounts for possible handling-related degradation. Mass analysis alone cannot establish every stereochemical feature or phosphitylation position.
Use condition
Discuss a suitable water-content test, residual-solvent requirements, and solution concentration where relevant. Packaging can be planned around the intended use pattern. Storage temperature, reconstitution solvent, and use period follow the exact reagent and available evidence rather than a class-wide shelf-life claim.
Functional product
When a coupling test is included, assess the final conjugate after the intended cleavage and deprotection steps. LC-MS and suitable separation can help distinguish conjugated, unconjugated, and related products. Reagent identity data remain separate from the functional test report.
Research applications
GalNAc is used in oligonucleotide ligand research, including ASGPR-related studies. The reagent provides a chemical route to a defined construct; receptor binding, uptake, activity, and safety require their own experimental evaluation.
Introduce a defined ligand at a supported terminal or internal position. The building-block architecture and synthesis program determine the accessible construct. Ligand incorporation does not by itself establish delivery or biological performance.
Compare valency, linker spacing, branch scaffold, or incorporation position while keeping other selected variables consistent. Each design remains a distinct reagent and conjugate, with structure-specific coupling and characterization requirements.
Evaluate reagent concentration, activator exposure, coupling time, and downstream deprotection in a defined process. The resulting data support that process-development question rather than a universal compatibility claim.
A defined synthesis project
The intended final construct defines the reagent architecture. The project then separates precursor synthesis, P(III) reagent quality, and any requested functional demonstration.
Project brief
Share the ligand structure, valency, linker, incorporation position, support and activator, complete synthesis cycle, quantity, and QC requirements.

Confirm the ligand valency, linker, attachment point, terminal or internal location, and final protection-free structure. Determine whether continued chain extension is required.

Identify the OH that will be phosphitylated and groups that must remain protected. Review sensitivity to the planned synthesis and deprotection conditions.

Specify identity tests, 31P NMR, purity reporting, optional water analysis, packaging, and any solution-form requirements. Record the acceptance basis for each item.

Use the assessed route with handling appropriate to the P(III) functionality. Evaluate chemical condition and relevant related species before release against the agreed specification.

Perform the defined coupling study if included, then report the tested construct, conditions, and post-cleavage results. Provide sample-specific handling information with the reagent.
Project advantages
BOC Sciences connects ligand structure with the chemistry used to install it. This makes the proposal useful for both reagent selection and the evaluation of a particular solid-phase workflow.
Valency, linker, phosphitylation site, and continuation functionality are recorded explicitly, reducing ambiguity between similarly named GalNAc reagents.
Reagent identity and phosphorus integrity are assessed independently from coupling performance, so a material result is not mistaken for a complete process demonstration.
Dryness, packaging, and solution requirements are considered alongside the requested amount, with guidance tied to the actual structure and evidence.
Optional functional studies identify the exact construct and cycle tested, making their practical limits clear for subsequent process decisions.
One connected glycan platform
Related insights
Explore supporting information on synthesis, characterization, and material selection for your project.
Frequently asked questions
Answers to common questions about the requested structures, characterization, and project scope.
No. Internal incorporation requires an architecture that supports both attachment and subsequent chain extension, with a compatible protecting-group sequence. Some structures are terminal modifiers. The complete drawing and intended cycle determine the appropriate use.
Not necessarily. Phosphorus diastereomers can give distinct signals when a stereogenic phosphorus center is present in a chiral molecule. Assignments, peak integration, and any impurity interpretation depend on the structure and acquisition conditions and should be supported by additional data.
The project defines handling and packaging appropriate to the P(III) reagent, with optional suitable water analysis and phosphorus-species assessment. Storage and solution-use guidance are set for the particular material; a universal shelf life is not assumed.
No. Purity is a material attribute measured by a particular method. Coupling compatibility requires evaluation with the relevant support, activator, concentration, sequence, and downstream cleavage and deprotection conditions.
They can be reviewed as different reagent architectures. Provide each complete structure and the intended final oligonucleotide arrangement. Valency, spacing, linker, and incorporation position must be considered separately rather than assuming equal behavior.
The core scope is synthesis of the specified phosphoramidite reagent. A coupling study or finished conjugate requires an additional defined scope, including sequence, backbone, scale, purification, and analytical expectations.
Define the research material your project needs
Send BOC Sciences the complete ligand and linker drawing, intended incorporation position, synthesis cycle, and required amount. Include phosphorus NMR, water-content, purity, packaging, and coupling-test requirements where relevant. We can review a project-specific reagent and evidence package that connects the molecular design with your research oligonucleotide workflow.
Contact BOC Sciences to discuss target-specific feasibility, specifications, and the required analytical package. Materials are intended for research use.